A Drug Shows Amyloid Reduction in Early Alzheimer’s
According to a recent article in Biospace, Eisai Pharmaceutical and Biogen Biotechnology recently announced updates to their Phase IIB study 201 and a five-year open-label extension (OLE) studies using lecanemab…